BETTERLIFE PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0795 USD | +5.58% |
|
+10.57% | +65.62% |
| Apr. 03 | BetterLife Pharma Inc. announced that it has received CAD 1.168 million in funding | CI |
| Mar. 04 | BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in funding | CI |
Valuation
| Fiscal Period: January | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 204.7 | 22.43 | 24.25 | 69.66 | 17.33 | 13.32 |
| Enterprise Value (EV) 2 | 204.9 | 25.85 | 26.27 | 70.01 | 17.47 | 13.39 |
| P/E ratio | -1,639 x | -2.29 x | -1.09 x | -1.01 x | -1.26 x | -1.36 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -222 x | -4.37 x | -3.15 x | -8.98 x | -1.76 x | -1.45 x |
| EV / FCF | -131 x | -11.2 x | -5.51 x | 46.4 x | -2.83 x | 5.98 x |
| FCF Yield | -0.77% | -8.97% | -18.2% | 2.15% | -35.4% | 16.7% |
| Price to Book | -4,511 x | 6.41 x | 9.16 x | -15.1 x | -4.47 x | -1.24 x |
| Nbr of stocks (in thousands) | 8,237 | 9,658 | 17,141 | 51,446 | 85,191 | 90,104 |
| Reference price 3 | 24.85 | 2.322 | 1.415 | 1.354 | 0.2035 | 0.1478 |
| Announcement Date | 5/1/18 | 5/3/19 | 6/1/20 | 5/31/21 | 5/31/22 | 5/31/23 |
1CAD in Million2USD in Million3CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: January | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -0.9227 | -5.919 | -8.337 | -7.797 | -9.951 | -9.239 |
| EBIT 1 | -0.9478 | -6.82 | -9.323 | -7.954 | -9.97 | -9.257 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.1212 | -9.146 | -19.59 | -36.35 | -11.99 | -9.373 |
| Net income 1 | -0.1212 | -9.146 | -19.59 | -36.35 | -12.16 | -9.373 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.0152 | -1.014 | -1.303 | -1.345 | -0.1611 | -0.1083 |
| Free Cash Flow 1 | -1.567 | -2.318 | -4.77 | 1.507 | -6.179 | 2.238 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/1/18 | 5/3/19 | 6/1/20 | 5/31/21 | 5/31/22 | 5/31/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: January | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.14 | 3.42 | 2.02 | 0.35 | 0.14 | 0.07 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.1481 x | -0.5783 x | -0.2424 x | -0.0443 x | -0.014 x | -0.00776 x |
| Free Cash Flow 1 | -1.57 | -2.32 | -4.77 | 1.51 | -6.18 | 2.24 |
| ROE (net income / shareholders' equity) | 15.9% | -530% | -637% | 3,717% | 286% | 164% |
| ROA (Net income/ Total Assets) | -229% | -94% | -62.8% | -103% | -493% | -936% |
| Assets 1 | 0.0528 | 9.729 | 31.19 | 35.16 | 2.466 | 1.001 |
| Book Value Per Share 2 | -0.0100 | 0.3600 | 0.1500 | -0.0900 | -0.0500 | -0.1200 |
| Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.1600 | 0 | 0 | 0 |
| Capex | - | - | 0.54 | 0.01 | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 5/1/18 | 5/3/19 | 6/1/20 | 5/31/21 | 5/31/22 | 5/31/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +65.62% | 8.74M | |
| -3.17% | 102B | |
| +1.95% | 96.29B | |
| +2.15% | 22.18B | |
| -15.39% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -15.70% | 16.36B | |
| +5.34% | 13.97B | |
| +32.92% | 12.17B |
- Stock Market
- Equities
- BETRF Stock
- Financials BetterLife Pharma Inc.
